mepyramine
Small moleculeapproved
Approved
Aug 7, 1973
Pyrabrom (also known as mepyramine 8-bromotheophyllinate) is a pharmaceutical preparation that causes antidiuresis under conditions of water load. However, under conditions of salt load Pyrabrom increases the speed of urinary excretion. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 4 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2024 (NCT06312254)
Timeline
1970s
- Aug 7, 1973
Earliest FDA Approval
- Aug 7, 1973
Impax Laboratories — Marketing Organization
1980s
- Oct 29, 1982
Watson Pharmaceuticals — Marketing Organization
Indications
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
prefrin-a
with phenylephrine
Approval history
- approvedAug 7, 1973
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(CN(CCN(C)C)c2ccccn2)cc1- Mol. weight
- 285.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Topical
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL511 ↗
- WikipediaMepyramine ↗
- NCATS360MH2GO0I ↗
- ChEMBLCHEMBL1201006 ↗
- ChEMBLCHEMBL1200443 ↗
- NCATSHPE317O9TL ↗
Also known as
- mepyramine
- mepyramine
- mepyramine
- mepyramine
- mepyramine
- mepyramine
- n-[(4-methoxyphenyl)methyl]-n',n'-dimethyl-n-2-pyridinyl-1,2-ethanediamine
- n-[(4-methoxyphenyl)methyl]-n',n'-dimethyl-n-2-pyridinyl-1,2-ethanediamine
- n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine
- n',n'-dimethyl-n-(p-methoxybenzyl)-n-(2-pyridyl)ethylenediamine
- n-(p-methoxybenzyl)-n',n'-dimethyl-n-(alpha-pyridyl)ethylenediamine
- n-(p-methoxybenzyl)-n',n'-dimethyl-n-(alpha-pyridyl)ethylenediamine
- prefrin-a
- prefrin-a
- pyranisamine
- pyranisamine
- pyranisamine
- pyrilamine
- pyrilamine
- pyrilamine
- pyrilamine
- pyrilamine
- pyrilamine
- pyrilamine
- pyrilamine
- pyrilamine maleate
- pyrilamine maleate
- pyrilamine maleate
- pyrilamine maleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06312254 | N/A | Apr 30, 2024 | Aalborg University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aalborg University | Academic/Hospital | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Allergan | For profit | NDA2 | — |
| Impax Laboratories | For profit | MKTG | Aug 7, 1973 |
| Smith, Kline & French | For profit | NDA | — |
| Watson Pharmaceuticals | For profit | MKTG | Oct 29, 1982 |